Patents by Inventor Andres Pablo Montefeltro

Andres Pablo Montefeltro has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240026357
    Abstract: A composition of matter comprising a synthetic miR-135 molecule comprising a nucleic acid sequence of a miR-135b as set forth in SEQ ID NO: 37, and a complementary strand as set forth in SEQ ID NO: 40 is disclosed. A conjugate comprising a composition of matter comprising a synthetic miR-135 molecule and a cell-targeting moiety is also disclosed.
    Type: Application
    Filed: July 14, 2023
    Publication date: January 25, 2024
    Applicants: Yeda Research and Development Co. Ltd., miCure Therapeutics Ltd.
    Inventors: Alon CHEN, Sharon MANASHIROV, Andres Pablo MONTEFELTRO
  • Publication number: 20230165265
    Abstract: The invention relates to a structured fat system for use in food applications. The invention also relates to the use of a structured fat system for reducing the trans- and saturated fat content of a food product.
    Type: Application
    Filed: April 30, 2021
    Publication date: June 1, 2023
    Inventors: Andres Pablo MONTEFELTRO, Armando LARA CAMBIL, Raquel REVILLA SANCHEZ, Silvia BAENA CHICO, Nuria JIMENEZ GARCIA
  • Patent number: 10125363
    Abstract: The invention provides a conjugate comprising (i) a selectivity agent which binds specifically to one or more neurotransmitter transporters selected from the group consisting of a dopamine transporter (DAT), serotonin transporter (SERT) or a norepinephrine transporter (NET) and (ii) a nucleic acid capable of specifically binding to a target molecule which is expressed in the same cell as the neurotransmitter transporter wherein said target molecule is ?-synuclein or the mRNA encoding ?-synuclein. The conjugates of the present invention are useful for the delivery of the nucleic acid to a cell of interest and thus, for the treatment of diseases which require a down-regulation of the protein encoded by the target nucleic acid as well as for the delivery of imaging agents to the cells for diagnostic purposes.
    Type: Grant
    Filed: July 20, 2015
    Date of Patent: November 13, 2018
    Assignee: nLife Therapeutics, S.L.
    Inventors: Andrés Pablo Montefeltro, Gabriel Alvarado Urbina, Analia Bortolozzi Biassoni, Francesc Artigas Pérez, Miquel Vila Bover, Maria del Carmen Carmona Orozco
  • Patent number: 10071163
    Abstract: The invention provides a conjugate comprising (i) a nucleic acid which is complementary to a target nucleic acid sequence and which expression prevents or reduces expression of the target nucleic acid and (ii) a selectivity agent which is capable of binding with high affinity to a neurotransmitter transporter. The conjugates of the present invention are useful for the delivery of the nucleic acid to a cell of interests and thus, for the treatment of diseases which require a down-regulation of the protein encoded by the target nucleic acid as well as for the delivery of imaging agents to the cells for diagnostic purposes.
    Type: Grant
    Filed: November 23, 2015
    Date of Patent: September 11, 2018
    Assignee: nLife Therapeutics, S.L.
    Inventors: Andrés Pablo Montefeltro, Gabriel Alvarado Urbina, Analia Bortolozzi Biassoni, Francesc Artigas Pérez, Miquel Vila Bover, Maria del Carmen Carmona Orozco
  • Patent number: 9938525
    Abstract: The invention provides a conjugate comprising (i) a nucleic acid which is complementary to a target nucleic acid sequence and which expression prevents or reduces expression of the target nucleic acid and (ii) a selectivity agent which is capable of binding with high affinity to a receptor which can be internalized by the cell in response to the binding of said selectivity agent. The conjugates of the present invention are useful for the delivery of the nucleic acid to cell of interests and thus, for the treatment of diseases which require a down-regulation of the protein encoded by the target nucleic acid as well as for the delivery of contrast agents to the cells for diagnostic purposes.
    Type: Grant
    Filed: October 25, 2013
    Date of Patent: April 10, 2018
    Assignee: NLIFE THERAPEUTICS, S.L.
    Inventors: Maria del Carmen Carmona Orozco, Andrés Pablo Montefeltro, Gabriel G. Alvarado, Analia Bortolozzi, Raquel Revilla-Sanchez
  • Publication number: 20160235856
    Abstract: The invention provides a conjugate comprising (i) a nucleic acid which is complementary to a target nucleic acid sequence and which expression prevents or reduces expression of the target nucleic acid and (ii) a selectivity agent which is capable of binding with high affinity to a neurotransmitter transporter. The conjugates of the present invention are useful for the delivery of the nucleic acid to a cell of interests and thus, for the treatment of diseases which require a down-regulation of the protein encoded by the target nucleic acid as well as for the delivery of imaging agents to the cells for diagnostic purposes.
    Type: Application
    Filed: November 23, 2015
    Publication date: August 18, 2016
    Inventors: Andrés Pablo MONTEFELTRO, Gabriel Alvarado Urbina, Analia Bortolozzi Biassoni, Francesc Artigas Pérez, Miquel Vila Bover, Maria del Carmen Carmona Orozco
  • Publication number: 20160083726
    Abstract: The invention provides a conjugate comprising (i) a selectivity agent which binds specifically to one or more neurotransmitter transporters selected from the group consisting of a dopamine transporter (DAT), serotonin transporter (SERT) or a norepinephrine transporter (NET) and (ii) a nucleic acid capable of specifically binding to a target molecule which is expressed in the same cell as the neurotransmitter transporter wherein said target molecule is ?-synuclein or the mRNA encoding ?-synuclein. The conjugates of the present invention are useful for the delivery of the nucleic acid to a cell of interest and thus, for the treatment of diseases which require a down-regulation of the protein encoded by the target nucleic acid as well as for the delivery of imaging agents to the cells for diagnostic purposes.
    Type: Application
    Filed: July 20, 2015
    Publication date: March 24, 2016
    Inventors: Andrés Pablo MONTEFELTRO, Gabriel Alvarado Urbina, Analia Bortolozzi Biassoni, Francesc Artigas Pérez, Miquel Vila Bover, Maria del Carmen Carmona Orozco
  • Patent number: 9193969
    Abstract: The invention provides a conjugate comprising (i) a nucleic acid which is complementary to a target nucleic acid sequence and which expression prevents or reduces expression of the target nucleic acid and (ii) a selectivity agent which is capable of binding with high affinity to a neurotransmitter transporter. The conjugates of the present invention are useful for the delivery of the nucleic acid to a cell of interests and thus, for the treatment of diseases which require a down-regulation of the protein encoded by the target nucleic acid as well as for the delivery of imaging agents to the cells for diagnostic purposes.
    Type: Grant
    Filed: April 19, 2011
    Date of Patent: November 24, 2015
    Assignee: nLife Therapeutics, S.L.
    Inventors: Andrés Pablo Montefeltro, Gabriel Alvarado Urbina, Analia Bortolozzi Biassoni, Francesc Artigas Pérez, Miquel Vila Bover, Maria del Carmen Carmona Orozco
  • Publication number: 20150315575
    Abstract: The invention provides a conjugate comprising (i) a nucleic acid which is complementary to a target nucleic acid sequence and which expression prevents or reduces expression of the target nucleic acid and (ii) a selectivity agent which is capable of binding with high affinity to a receptor which can be internalised by the cell in response to the binding of said selectivity agent. The conjugates of the present invention are useful for the delivery of the nucleic acid to cell of interests and thus, for the treatment of diseases which require a down-regulation of the protein encoded by the target nucleic acid as well as for the delivery of contrast agents to the cells for diagnostic purposes.
    Type: Application
    Filed: October 25, 2013
    Publication date: November 5, 2015
    Inventors: Maria del Carmen CARMONA OROZCO, Andrés Pablo MONTEFELTRO, Gabriel G. ALVARADO, Analia BORTOLOZZI, Raquel REVILLA-SANCHEZ
  • Patent number: 9084825
    Abstract: The invention provides a conjugate comprising (i) a selectivity agent which binds specifically to one or more neurotransmitter transporters selected from the group consisting of a dopamine transporter (DAT), serotonin transporter (SERT) or a norepinephrine transporter (NET) and (ii) a nucleic acid capable of specifically binding to a target molecule which is expressed in the same cell as the neurotransmitter transporter wherein said target molecule is ?-synuclein or the mRNA encoding ?-synuclein. The conjugates of the present invention are useful for the delivery of the nucleic acid to a cell of interest and thus, for the treatment of diseases which require a down-regulation of the protein encoded by the target nucleic acid as well as for the delivery of imaging agents to the cells for diagnostic purposes.
    Type: Grant
    Filed: October 28, 2013
    Date of Patent: July 21, 2015
    Assignee: nLife Therapeutics, S.L.
    Inventors: Andrés Pablo Montefeltro, Gabriel Alvarado Urbina, Analia Bortolozzi Biassoni, Francesc Artigas Pérez, Miquel Vila Bover, Maria del Carmen Carmona Orozco
  • Publication number: 20140120158
    Abstract: The invention provides a conjugate comprising (i) a selectivity agent which binds specifically to one or more neurotransmitter transporters selected from the group consisting of a dopamine transporter (DAT), serotonin transporter (SERT) or a norepinephrine transporter (NET) and (ii) a nucleic acid capable of specifically binding to a target molecule which is expressed in the same cell as the neurotransmitter transporter wherein said target molecule is ?-synuclein or the mRNA encoding ?-synuclein. The conjugates of the present invention are useful for the delivery of the nucleic acid to a cell of interest and thus, for the treatment of diseases which require a down-regulation of the protein encoded by the target nucleic acid as well as for the delivery of imaging agents to the cells for diagnostic purposes.
    Type: Application
    Filed: October 28, 2013
    Publication date: May 1, 2014
    Inventors: Andrés Pablo MONTEFELTRO, Gabriel Alvarado Urbina, Analia Bortolozzi Biassoni, Francesc Artigas Pérez, Miquel Vila Bover
  • Publication number: 20120322991
    Abstract: The invention provides a conjugate comprising (i) a nucleic acid which is complementary to a target nucleic acid sequence and which expression prevents or reduces expression of the target nucleic acid and (ii) a selectivity agent which is capable of binding with high affinity to a neurotransmitter transporter. The conjugates of the present invention are useful for the delivery of the nucleic acid to a cell of interests and thus, for the treatment of diseases which require a down-regulation of the protein encoded by the target nucleic acid as well as for the delivery of imaging agents to the cells for diagnostic purposes.
    Type: Application
    Filed: April 19, 2011
    Publication date: December 20, 2012
    Applicant: NLIFE THERAPEUTICS, S.L.
    Inventors: Andres Pablo Montefeltro, Gabriel Alvarado Urbina, Analia Bortolozzi Biassoni, Francesc Artigas Perez, Miquel Vila Bover